More Videos
SPECIAL REPORT
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- HP Comes in As Expected; Is It Time to Buy?
- Prepare For Large Decline In Stocks, Next Year?
- Hewlett-Packard Profit Rises, Matches Guidance
- Wave of Debt Payments Facing US Government
- Nov. 23: Unusual Volume Leaders
- Paul: Audit the Fed
- The Social Media Gaming Threat
- Holiday Travel Outlook
- Lyondell Urged to Consider Reliance Takeover Offer
- Can Murdoch Help Bing Challenge Google and Shift the Content Equation?
- HP's Mark Hurd
- HP Comes in As Expected; Is It Time to Buy?
- 9 Stocks That Play Rising Water Costs: Strategists
- Weis' Deal Likely Won't Change Big Money Contracts
- Gold Prices Can Double in 3 Years: Portfolio Manager
- Nov. 23: Unusual Volume Leaders
- Help Wanted—Please Run $4 Billion University
- Apple Comes to AT&T's Rescue
- More Consumers Giving 'Black Friday' the Cold Shoulder
- Prepare For Large Decline In Stocks, Next Year?
- Tuesday's Heavy Dose of Data to Dictate 'Risk' Behavior
- Hewlett-Packard Earnings Rise, Match Guidance
- HP Comes in As Expected; Is It Time to Buy?
- Cramer: What Monday’s Housing Number Really Means
- Why the Dollar Will Likely Stay Weak for Some Time
- Bear, Lehman Execs Weren't Wiped Out by Crisis: Study
- How Real Estate Investors Skew Housing's Reality
PHARMA'S MARKET VIDEO
Cholesterol Drug Battle: Niaspan vs. Zetia 
16 Nov 2009Cardiologist Grades Cholesterol Drug Study 16 Nov 2009
Merck's Cholesterol Drugs Under Pressure 16 Nov 2009
Cholesterol Drug Battle: Merck vs. Abbott Labs 16 Nov 2009
Cholesterol Drug Battle 16 Nov 2009
Novo Nordisk CEO on Diabetes Epidemic 13 Nov 2009
RSS FEED
Pharma's Market
Text Size 
 |
CNBC.com |
] is headquartered in San Diego. Like a lot of companies, though, it's incorporated in Delaware. But, if a couple of major shareholders get their way, AMLN could reincorporate in an unlikely state. Try North Dakota. Yep, as in Fargo.
David Kliff, who writes "The Diabetic Investor," over the weekend called my attention to a quirky little nugget in a new SEC filing. Activist investors Carl Icahn and another big fund with a large stake in AMLN not only want to put a bunch of their own people on the Board of Directors, but they want the company to pick up legal stakes from Delaware and move them to the Northern Plains.
In a note to his subscribers, Kliff wrote, "It appears Eastbourne (the other investment fund) and Icahn are joining forces with the ultimate goal being the sale of the company. This is further reinforced by the request that the company reincorporate in North Dakota."
Why North Dakota, you ask? Late last year Icahn blogged about what he sees as the shareholder benefits of incorporating in ND.
Last year Icahn tried and failed to get his people of the board of Biogen Idec [BIIB
Loading...
()
] , but he suceeded several years ago in getting control of ImClone Systems which was recently sold to Eli Lilly [LLY
Loading...
()
] . If he and Eastbourne can carry the day at Amylin, Lazard Capital Markets analyst Matthew Osbourne, in a research note to clients, says, "Unlike some companies that have a staggered board of directors (meaning that only a few members are voted for reelection each year), all of Amylin's 12-member board are voted on each year. An ability to elect at least five new members could swiftly change the direction of the company." LCM makes a market in AMLN.
Amylin shares have lost about two-thirds of their value over the past year. Investors are concerned about a looming change to the label by the FDA on the diabetes drug Byetta over reports of rare cases of pancreatitis, what that possibly means to the fate and timeline of a once-a-week version of Byetta that's in late-stage development and the potential competition soon from a one-a-day drug out of Novo Nordisk [NVO
Loading...
()
] . In addition, the Street was disappointed when Amylin didn't give Byetta sales guidance for this year on its recent earnings conference call. All of that may explain why the newly disclosed strategic maneuvering by Icahn and Eastbourne isn't doing much to move the stock.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes